StockNews.com Begins Coverage on Revance Therapeutics (NASDAQ:RVNC)

StockNews.com started coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a report released on Tuesday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Separately, Needham & Company LLC reaffirmed a “hold” rating on shares of Revance Therapeutics in a report on Friday, January 17th. Eight analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, Revance Therapeutics currently has an average rating of “Hold” and a consensus price target of $8.45.

Revance Therapeutics Price Performance

Shares of NASDAQ RVNC opened at $3.65 on Tuesday. The firm’s 50-day moving average price is $3.65 and its 200-day moving average price is $3.72. The company has a market cap of $381.02 million, a PE ratio of -1.89 and a beta of 0.90. Revance Therapeutics has a 52-week low of $2.30 and a 52-week high of $6.65.

Hedge Funds Weigh In On Revance Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in RVNC. Natixis purchased a new position in shares of Revance Therapeutics in the fourth quarter worth approximately $31,000. Two Sigma Securities LLC purchased a new position in Revance Therapeutics during the fourth quarter valued at approximately $35,000. Alpine Global Management LLC purchased a new position in Revance Therapeutics during the fourth quarter valued at approximately $37,000. RPO LLC purchased a new position in Revance Therapeutics during the fourth quarter valued at approximately $55,000. Finally, Fairfax Financial Holdings Ltd. Can purchased a new position in Revance Therapeutics during the fourth quarter valued at approximately $64,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.